Looking beyond the headlines
毫不奇怪，上周发布的一些最大的科学新闻国际肝脏大会（ILC）在巴塞罗那与丙型肝炎治疗方面的持续进展有关。作为一名公共卫生和卫生系统研究人员，我很高兴看到一些ILC参与者呼吁关注直接作用抗病毒药（DAA）革命正在展开的更大背景。
是的，从生物医学的角度来看，DAA治疗方案为我们提供了完全消除丙型肝炎C的手段 - 该领域科学家的一项显着成就。对于我们这些工作从整体上解决人口健康的人来说，ILC还能提供什么？
These were some points that jumped out at me during the four-day meeting.
Thinking beyond direct-acting antiviral cure rates
Progress on the hepatitis C virus (HCV) treatment front is fantastic, but let’s not conflate this with progress toward eliminating HCV.
首先，丙型肝炎病毒（HCV）治疗方面的进展是很棒的，但不要将其与消除HCV的进步混为一谈。在一次会议上，该会议旨在解决民间社会为推动HCV淘汰进展的努力，Rafael Bengoa的Deusto大学aptly noted that no disease can be conquered through clinical advances alone.
由于合理的公共卫生策略和大量财务资源的承诺，已充分或几乎完全消除的少数疾病占据了这种地位。
Thinking beyond hepatitis C
其次，公众对HCV的关注受到了极大的欢迎，但我们不能让它掩盖人们用其他形式的病毒性肝炎挣扎的人的未满足的健康需求。在世界某些地区，丙型肝炎病毒（HBV）比HCV承担着更大的疾病负担。
也有一些看似资源良好的卫生系统的国家，但预防病毒性肝炎的差距不可原谅。
例如，在一个研讨会上European Association for the Study of the Liver和世界肝炎联盟组织的是讨论全世界国家准备的准备世界卫生组织有史以来第一个病毒肝炎消除靶标，，，，Anna S. Lok of美国肝病研究协会指出美国只有74％出生剂量HBV疫苗覆盖率。
Thinking beyond viral hepatitis
追求消除病毒肝炎并不是肝病领域可以促进主要人口健康增长的唯一途径。
第三，追求病毒性肝炎并不是肝病领域可以促进主要人口健康增长的唯一途径。南安普敦大学的尼克·谢隆（Nick Sheron）在alcohol-related harm以及诸如最低单位定价和营销法规之类的政策的潜力，以对该问题产生真正的影响。
Professor Sheron discussed the very clear link between alcohol consumption and liver mortality in the European Union (EU) and explained how national alcohol policies are greatly driving trends in alcohol consumption.
He closed his talk with the striking assertion that if the EU countries with the highest levels of liver mortality could be brought in line with the average for EU countries, 14,000 deaths per year would be prevented. If all EU countries were to reduce liver mortality to the lowest level seen in the region, this would prevent 46,000 deaths per year.
In sum, the ILC provided some welcome reminders of the need for a broad swath of experts to focus intently on their own specific goals while also recognizing how and why the other pieces of the picture matter.
有用的链接：
Joint Society Statement for Elimination of Viral Hepatitis
肝病学，医学和政策has launched with BioMed Central. For more information, visit:www.hmap.biomedcentral.com。
Comments